Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SSX family member 13, pseudogene (SSX13P) is classified as a pseudogene within the SSX gene family, which includes several protein-coding members involved in chromosomal translocations in synovial sarcoma (notably SSX1, SSX2, and rarely SSX4)[1][3][4]. Pseudogenes are DNA sequences similar to known genes but typically do not encode functional proteins due to mutations or lack of regulatory elements. The SSX13P gene does not appear to produce protein or exhibit any functional biological activity and is not implicated in human diseases or targeted by therapies[1]. Although SSX family genes are known for their role as cancer-testis antigens and in specific chromosomal translocations in synovial sarcoma, pseudogene members like SSX13P do not participate in these events. SSX13P may be used as a reference sequence in genomics studies but is not a valid drug or biomarker target[1][3][4]. SSX13P is a non-functional pseudogene with no protein product, biological function, or validated role in disease, drug targeting, or molecular therapy. Its nomenclature is correct, and there are no safety or clinical concerns associated with it as a molecular target[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SSX family member 13, pseudogene (SSX13P).